Hinge Health and Omada Health reawakened the digital health IPO market. But most late-stage healthcare startups aren't ready ...

Shares of Omada Health finished their trading debut on the Nasdaq above their IPO price after the virtual chronic care firm ...

The IPO market is starting to feel healthier. Omada Health, a 14-year-old company providing virtual care for chronic conditions like diabetes and hypertension between office visits, closed its first ...

Many healthcare experts are calling Omada Health and Hinge Health's IPO debuts a success, though it's still early days.

Hinge Health and Omada Health. During a recent panel discussion, venture capitalists shared lessons learned about health tech ...

The company is not yet profitable. In 2023, Omada reported a net loss of $67.5 million, and that shrank to $47 million in 2024. The company reported a net loss of $9.4 million in the first quarter ...

Omada Health, a virtual chronic care provider, priced its IPO at $19 per share, at the midpoint of its $18 to $20 per share price range. The company said in a press release Thursday it sold 7.9 ...

Omada Health has become the second major digital health company to debut on the public markets this year, with an initial public offering valued at $1.1 billion.The company follows a successful ...

Omada is trading publicly after 14 years of providing support to patients with weight-related chronic illnesses. Leadership sees the current moment as the perfect time for an IPO, as GLP-1 drugs ...

Virtual chronic care provider Omada Health said on Thursday it had raised $150 million in its U.S. initial public offering, another sign of recovering investor appetite for new stocks.

Omada Health just became the second digital health company to IPO this year. The chronic care company saw its shares jump Friday morning by over 38% above its initial price.

Omada Health priced its IPO at $19 per share on Thursday, in the middle of the expected range.. The virtual chronic care company said in a press release that 7.9 million shares are being sold in ...